Johan Ahlgren

Loss of Cdk2 and Cyclin A2 Impairs Cell Proliferation and Tumorigenesis

Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018

The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2−negative metastatic breast cancer: experience from the patient perspective

Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Cancer treatment and survivorship statistics, 2022

Breast cancer

Update of the evolution of breast cancer incidence in relation to hormone replacement therapy use in Belgium

Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review

Cell cycle proteins as promising targets in cancer therapy

Regional Nodal Management in the Setting of Up-Front Surgery

New Horizons for Diagnostics and Therapeutic Applications of Graphene and Graphene Oxide

Update on Prevalence of Pain in Patients With Cancer: Systematic Review and Meta-Analysis

Pyroptosis: mechanisms and diseases

Sexual dysfunction and infertility as late effects of cancer treatment

Capecitabine: A review

Pyroptosis: A new frontier in cancer

Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy

Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population‐based lymph node negative breast cancer cohort

Health-related quality of life among breast cancer patients in Lebanon

Estimates of cancer incidence and mortality in Europe in 2008

Quantification of changes in breast cancer incidence and mortality since 1990 in 35 countries with Caucasian-majority populations

The history and future of targeting cyclin-dependent kinases in cancer therapy

Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)

Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment

Noncovalent Functionalization of Graphene and Graphene Oxide for Energy Materials, Biosensing, Catalytic, and Biomedical Applications

Breast Cancer Statistics, 2022

Cancer treatment and survivorship statistics, 2016

Carbon Nanomaterials for Biological Imaging and Nanomedicinal Therapy

Cancer treatment and survivorship statistics, 2019

Reactive Oxygen Species (ROS)-Based Nanomedicine

Heteroatom-doped graphene materials: syntheses, properties and applications

Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment: a Review

Breast cancer statistics, 2013

The impact of the COVID‐19 pandemic on cancer diagnosis based on pathology notifications: A comparison across the Nordic countries during 2020

Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer

Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial

Health-related quality of life among women with breast cancer – a population-based study

Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study

Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer

Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years

Prostate cancer diagnosis, staging, and treatment in Sweden during the first phase of the COVID-19 pandemic

Regional Differences in Breast Cancer Survival Despite Common Guidelines

Sex Differences in Fertility-Related Information Received by Young Adult Cancer Survivors

Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial